Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

Kioa Lente Wijnsma; Rob ter Heine; Dirk Jan A.R. Moes; Saskia Langemeijer; Saskia E.M. Schols; Elena B. Volokhina; Lambertus P. van den Heuvel; Jack F.M. Wetzels; Nicole C.A.J. van de Kar; Roger J. Brüggemann

doi:10.1007/s40262-019-00742-8

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

Kioa Lente Wijnsma
, Rob ter Heine
, Dirk Jan A.R. Moes
, Saskia Langemeijer
, Saskia E.M. Schols
, Elena B. Volokhina
, Lambertus P. van den Heuvel
, Jack F.M. Wetzels
, Nicole C.A.J. van de Kar
, Roger J. Brüggemann

Research output: Contribution to journal › Review article › peer-review

108 Citations (Scopus)

Abstract

Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.

Original language	English
Pages (from-to)	859-874
Number of pages	16
Journal	Clinical Pharmacokinetics
Volume	58
Issue number	7
DOIs	https://doi.org/10.1007/s40262-019-00742-8
Publication status	Published - 1 Jul 2019
Externally published	Yes

Access to Document

10.1007/s40262-019-00742-8

Cite this

Wijnsma, K. L., ter Heine, R., Moes, D. J. A. R., Langemeijer, S., Schols, S. E. M., Volokhina, E. B., van den Heuvel, L. P., Wetzels, J. F. M., van de Kar, N. C. A. J., & Brüggemann, R. J. (2019). Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical Pharmacokinetics, 58(7), 859-874. https://doi.org/10.1007/s40262-019-00742-8

@article{8519a5ffe2d2476196e61695f8b2d9f9,

title = "Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab",

abstract = "Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.",

author = "Wijnsma, \{Kioa Lente\} and \{ter Heine\}, Rob and Moes, \{Dirk Jan A.R.\} and Saskia Langemeijer and Schols, \{Saskia E.M.\} and Volokhina, \{Elena B.\} and \{van den Heuvel\}, \{Lambertus P.\} and Wetzels, \{Jack F.M.\} and \{van de Kar\}, \{Nicole C.A.J.\} and Br{\"u}ggemann, \{Roger J.\}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = jul,

day = "1",

doi = "10.1007/s40262-019-00742-8",

language = "English",

volume = "58",

pages = "859--874",

journal = "Clinical Pharmacokinetics",

issn = "0312-5963",

publisher = "Adis",

number = "7",

}

Wijnsma, KL, ter Heine, R, Moes, DJAR, Langemeijer, S, Schols, SEM, Volokhina, EB, van den Heuvel, LP, Wetzels, JFM, van de Kar, NCAJ & Brüggemann, RJ 2019, 'Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab', Clinical Pharmacokinetics, vol. 58, no. 7, pp. 859-874. https://doi.org/10.1007/s40262-019-00742-8

TY - JOUR

T1 - Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

AU - Wijnsma, Kioa Lente

AU - ter Heine, Rob

AU - Moes, Dirk Jan A.R.

AU - Langemeijer, Saskia

AU - Schols, Saskia E.M.

AU - Volokhina, Elena B.

AU - van den Heuvel, Lambertus P.

AU - Wetzels, Jack F.M.

AU - van de Kar, Nicole C.A.J.

AU - Brüggemann, Roger J.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.

AB - Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.

UR - https://www.scopus.com/pages/publications/85061756384

U2 - 10.1007/s40262-019-00742-8

DO - 10.1007/s40262-019-00742-8

M3 - Review article

C2 - 30758736

AN - SCOPUS:85061756384

SN - 0312-5963

VL - 58

SP - 859

EP - 874

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

IS - 7

ER -

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

Abstract

Access to Document

Fingerprint

Cite this